Antipsychotic Polypharmacy and High-dose Antipsychotic Therapy Compared to Antipsychotic Monotherapy at Standard Doses in Schizophrenia - a Systematic Review

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2024 Dec 10

PMID 39655766

Authors

Christopher Lawrence

Chloe Roberts

Chloe Galides

Samuel R Chamberlain

Ruihua Hou

Affiliations

Soon will be listed here.

Abstract

Background: Schizophrenia is considered to have a lifetime prevalence of around 1%. Up to 30% of patients diagnosed with schizophrenia are subsequently categorised as treatment resistant. Current guidelines advise against the use of antipsychotic polypharmacy (APP) or high-dose antipsychotic therapy (HDAT) in the treatment of schizophrenia; however, these treatment approaches continue to be used in up to 25% of cases.

Aims: This review was to evaluate the evidence for the efficacy and tolerability of APP and HDAT as an alternative to antipsychotic monotherapy at standard doses in the treatment of schizophrenia.

Methods: This is a systematic review. We searched PubMed, EMBASE and PsycINFO, for eligible trials published prior to 24 March 2023. The protocol was registered on PROSPERO (CRD42023408785). Quality assessment was conducted using the Revised Cochrane risk-of-bias tool for randomised trials.

Results: A total of 14 studies were included in this review. Two studies demonstrated clinically significant improvement with APP compared to standard treatment. There was no clear evidence that APP or HDAT is definitively less tolerable than antipsychotic monotherapy at a standard dose.

Conclusions: This review found limited evidence for the efficacy of APP and HDAT in the treatment of schizophrenia over the use of antipsychotic monotherapy at a standard dose. The relative tolerability was unclear. Management of treatment-resistant schizophrenia remains a prominent clinical issue and further research, including high-quality large-scale Randomised Controlled Trials (RCTs) of APP and HDAT in patients who have been unresponsive to clozapine, would be of significant benefit to the field of psychiatry.

References

Shim J, Shin J, Kelly D, Jung D, Seo Y, Liu K . Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007; 164(9):1404-10. DOI: 10.1176/appi.ajp.2007.06071075. View

Conley R, Tamminga C, Bartko J, Richardson C, Peszke M, Lingle J . Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998; 155(7):914-20. DOI: 10.1176/ajp.155.7.914. View

Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W . Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017; 16(1):77-89. PMC: 5269492. DOI: 10.1002/wps.20387. View

Volavka J, Czobor P, Sheitman B, Lindenmayer J, Citrome L, McEvoy J . Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002; 159(2):255-62. DOI: 10.1176/appi.ajp.159.2.255. View

Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H . Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2008; 23(6):455-63. DOI: 10.1002/hup.959. View

Chen J, Su Y, Bian Q, Wei L, Zhang R, Liu Y . Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015; 58:130-40. DOI: 10.1016/j.psyneuen.2015.04.011. View

Ermilov M, Gelfin E, Levin R, Lichtenberg P, Hashimoto K, Javitt D . A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Schizophr Res. 2013; 150(2-3):604-5. DOI: 10.1016/j.schres.2013.09.018. View

Kahn R, Sommer I, Murray R, Meyer-Lindenberg A, Weinberger D, Cannon T . Schizophrenia. Nat Rev Dis Primers. 2016; 1:15067. DOI: 10.1038/nrdp.2015.67. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

10.

Meltzer H, Bobo W, Roy A, Jayathilake K, Chen Y, Ertugrul A . A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008; 69(2):274-85. DOI: 10.4088/jcp.v69n0214. View

11.

Tiihonen J, Taipale H, Mehtala J, Vattulainen P, Correll C, Tanskanen A . Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019; 76(5):499-507. PMC: 6495354. DOI: 10.1001/jamapsychiatry.2018.4320. View

12.

Ray W, Chung C, Murray K, Hall K, Stein C . Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009; 360(3):225-35. PMC: 2713724. DOI: 10.1056/NEJMoa0806994. View

13.

Nielsen J, Emborg C, Gydesen S, Dybbro J, Aagaard J, Haderup K . Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2012; 32(2):173-8. DOI: 10.1097/JCP.0b013e318248dfb8. View

14.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

15.

Kreinin A, Novitski D, Weizman A . Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006; 21(2):99-103. DOI: 10.1097/01.yic.0000188216.92408.69. View

16.

Tollefson G, Birkett M, Kiesler G, Wood A . Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001; 49(1):52-63. DOI: 10.1016/s0006-3223(00)01026-x. View

17.

Hatta K, Otachi T, Sudo Y, Kuga H, Takebayashi H, Hayashi H . A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Res. 2012; 198(2):194-201. DOI: 10.1016/j.psychres.2012.01.006. View

18.

Burness C, Corbet C, Beyene K, Webby C, Nankivell C, Cabasag P . Factors predicting high-dose and combined antipsychotic prescribing in New Zealand: High-dose antipsychotic prescribing. Psychiatry Res. 2021; 302:113996. DOI: 10.1016/j.psychres.2021.113996. View

19.

Friedman J, Lindenmayer J, Alcantara F, Bowler S, Parak M, White L . Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology. 2011; 36(6):1289-95. PMC: 3077468. DOI: 10.1038/npp.2011.14. View

20.

Carnahan R, Lund B, Perry P, Chrischilles E . Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand. 2006; 113(2):135-41. DOI: 10.1111/j.1600-0447.2005.00589.x. View